Akari Therapeutics, Plc (AKTX)
Company Info
| ISIN | US00972G1085 |
|---|---|
| CUSIP | 00972G108 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $45.20M |
|---|---|
| EPS (TTM) | -$3.14 |
| Gross Profit (TTM) | -$13.00K |
| EBITDA (TTM) | -$13.57M |
| Year Range | $1.08 - $5.50 |
| Target Price | $80.00 |
| Short % | 0.08% |
| Short Ratio | 0.24 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Akari Therapeutics, Plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Akari Therapeutics, Plc had a return of 27.99% year-to-date (YTD) and 1.66% in the last 12 months. Over the past 10 years, Akari Therapeutics, Plc had an annualized return of -44.23%, while the S&P 500 had an annualized return of 10.58%, indicating that Akari Therapeutics, Plc did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 27.99% | 13.20% |
| 1 month | 44.16% | -1.28% |
| 6 months | 53.70% | 10.32% |
| 1 year | 1.66% | 18.23% |
| 5 years (annualized) | -36.63% | 12.31% |
| 10 years (annualized) | -44.23% | 10.58% |
Monthly Returns
The table below presents the monthly returns of AKTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -16.03% | -10.31% | -20.64% | -17.43% | 11.30% | 57.53% | 27.99% | ||||||
| 2023 | -0.66% | -26.09% | -47.33% | -0.33% | -2.32% | -3.90% | 46.82% | -36.90% | 25.40% | -13.67% | -13.49% | 5.76% | -66.80% |
| 2022 | -8.67% | -1.46% | -11.11% | -0.83% | -1.68% | -14.54% | 14.01% | 4.39% | -47.06% | -26.06% | 18.63% | -14.97% | -68.67% |
| 2021 | 36.76% | 32.41% | -21.19% | -21.97% | -12.86% | -3.62% | -6.36% | 13.58% | -11.41% | 1.84% | -1.81% | -7.98% | -18.92% |
| 2020 | 2.86% | 2.22% | -21.20% | 32.41% | 6.25% | 6.86% | -7.80% | -14.43% | 1.16% | -13.79% | 6.67% | 15.62% | 5.71% |
| 2019 | 28.01% | -9.94% | 97.79% | 0.00% | -46.93% | 6.32% | -6.93% | 10.64% | -17.79% | 11.11% | 8.42% | -15.05% | 11.46% |
| 2018 | -33.95% | -31.82% | -6.67% | 4.95% | -3.66% | 5.98% | -1.54% | -2.08% | 36.17% | -29.69% | -0.56% | -12.29% | -63.74% |
| 2017 | 13.64% | -18.62% | 70.05% | 35.41% | -59.11% | -24.80% | 0.87% | -23.66% | 72.96% | -30.13% | 13.29% | -10.91% | -38.49% |
| 2016 | -4.57% | -30.19% | 44.93% | 22.86% | -12.21% | -10.66% | -31.06% | 1.72% | -10.04% | 11.05% | -24.34% | -1.54% | -51.45% |
| 2015 | 20.83% | -84.48% | -15.56% | -1.32% | -41.56% | 32.33% | -1.72% | 347.37% | -5.90% | -20.40% | 1.57% | -25.25% | -69.79% |
| 2014 | 25.35% | -27.53% | 0.62% | -6.01% | -16.39% | 21.57% | -8.71% | 4.24% | 3.39% | -2.95% | -10.14% | -9.77% | -32.39% |
| 2013 | -5.00% | -15.79% | 0.00% | -50.00% | -29.00% | -71.60% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of AKTX is 56, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Akari Therapeutics, Plc (AKTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Akari Therapeutics, Plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Akari Therapeutics, Plc was 99.98%, occurring on Apr 11, 2024. The portfolio has not yet recovered.
The current Akari Therapeutics, Plc drawdown is 99.92%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.98% | May 23, 2013 | 2519 | Apr 11, 2024 | — | — | — |
Volatility
Volatility Chart
The current Akari Therapeutics, Plc volatility is 32.06%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Akari Therapeutics, Plc.
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |